Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele

American Journal of Pathology

Volumn 162, Issue 1, 2003, Pages 313-319

  Cook, David G ^a,b   Leverenz, James B ^a,b   McMillan, Pamela J ^a,b   Kulstad, J Jacob ^a,b   Ericksen, Sasha ^b   Roth, Richard A ^b   Schellenberg, Gerard D ^a,b   Jin, Lee Way ^b   Kovacina, Kristina S ^c   Craft, Suzanne ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ENOLASE; INSULIN; INSULINASE; MESSENGER RNA;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CELL LOSS; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INSULIN DEGRADATION; INSULIN METABOLISM; MALE; NERVE CELL; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RISK FACTOR;

EID: 0037219221     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63822-9     Document Type: Article

References (36)

1. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325
2. Shoji M, Golce TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, Younkin SG: Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992, 258:126-129
3. Selkoe DJ: Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180
4. Perez A, Morelli L, Cresto JC, Castano EM: Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000, 25:247-255
5. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ: Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000, 20:1657-1665
6. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman Jr P, Pyrek JS, Estus S, Hersh LB: Insulysin hydrolyzes amyloid β peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 2000, 20:8745-8749
7. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem 1998, 273:32730-32738
8. Sudoh S, Frosch MP, Wolf BA: Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002, 41:1091-1099
9. Edbauer D, Willem M, Lammich S, Steiner H, Haass C: Insulin-degrading enzyme rapidly removes the β-amyloid precursor protein intracellular domain (AICD). J Biol Chem 2002, 277:13389-13393
10. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C: Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001, 2:835-841
11. Yu C, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R, Sisodia SS: Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment γ: Evidence for distinct mechanisms involved in γ-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 2001, 276:43756-43760
12. Cao X, Sudhof TC: A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120
13. McLoughlin DM, Miller CC: The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. FEBS Lett 1996, 397:197-200
14. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ: The intracellular domain of the β-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 2001, 276:40288-40292
15. Kuo WL, Gehm BD, Rosner MR: Regulation of insulin degradation: Expression of an evolutionarily conserved insulin-degrading enzyme increases degradation via an intracellular pathway. Mol Endocrinol 1991, 5:1467-1476
16. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: Progress and potential. Endocr Rev 1998, 19:608-624
17. Authier F, Posner BI, Bergeron JJ: Insulin-degrading enzyme. Clin Invest Med 1996, 19:149-160
18. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000, 290:2302-2303
19. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM: Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000, 290:2304-2305
20. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG: Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000, 290:2303-2304
21. Bennett RG, Hamel FG, Duckworth WC: Characterization of the insulin inhibition of the peptidolytic activities of the insulin-degrading enzyme-proteasome complex. Diabetes 1997, 46:197-203
22. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K: Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70:146-152
23. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr D: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168
24. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991, 82:239-259
25. Shii K, Roth RA: Inhibition of insulin degradation by hepatoma cells after microinjection of monoclonal antibodies to a specific cytosolic protease. Proc Natl Acad Sci USA 1986, 83:4147-4151
26. McMillan PJ, Leverenz JB, Dorsa DM: Specific down-regulation of presenilin 2 gene expression is prominent during early stages of sporadic late-onset Alzheimer's disease. Brain Res Mol Brain Res 2000, 78:138-145
27. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frolich L, Bogerts B: Insulin-degrading enzyme in the Alzheimer's disease brain: Prominent localization in neurons and senile plaques. Neurosci Lett 1999, 263:161-164
28. Standl E, Kolb HJ: Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1984, 27:17-22
29. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G, Turic D, Hoogendoorn B, Kwon JM, Petersen RC, Tangalos E, Norton J, Morris JC, Bullock R, Liolitsa D, Lovestone S, Hardy J, Goate A, O'Donovan M, Williams J, Owen MJ, Jones L: Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet 2001, 109:646-652
30. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: Risk of dementia among persons with diabetes mellitus: A population-based cohort study Am J Epidemiol 1997, 145:301-308
31. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942
32. Pella R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262
33. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC: Identification of the major Aβ-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000, 6:143-150
34. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC: Neprilysin degrades both amyloid β peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001, 276:21895-21901
35. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC: Metabolic regulation of brain Aβ by neprilysin. Science 2001, 292:1550-1552
36. Yasojima K, Akiyama H, McGeer EG, McGeer PL: Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide. Neurosci Lett 2001, 297:97-100